🏢 官网IRARCTCodex · 实盘不做把握 9/10
北京时间·🕒 发布 04:01:00时区推断·⟳ 抓取 04:02:46回填·⚡ 决策 07-21 04:03:50·98.9 天前
Arcturus Therapeutics将参加Canaccord年度成长会议并进行炉边谈话
公司仅公告将于2026-08-11参加投资者会议并提供 webcast 链接，未披露临床、监管、合作、订单或财务增量。
📄 原文ARCT↗ 原文
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
Skip to main navigation Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference July 20…
不做 Arcturus Therapeutics（ARCT.US）
例行投资者会议参会公告，无明确业务、临床、监管或财务增量，不能形成正期望交易，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-20 · 扩散 low · price-in 风险 low ↗
关键理由
- 公司仅公告将于2026-08-11参加投资者会议并提供 webcast 链接，未披露临床、监管、合作、订单或财务增量。
主要风险
- 会议现场未来可能释放新信息，但当前这条公告本身不是可交易催化。
原文全文
展开原文 · 2,467 字
Skip to main navigation
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
July 20, 2026 at 4:01 PM EDT
PDF Version
SAN DIEGO --(BUSINESS WIRE)--Jul. 20, 2026--
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts :
Canaccord Genuity 46 th Annual Growth Conference (Fireside Chat)
Tuesday, August 11, 2026 ( 12:00 p.m. ET )
Webcast link can be found under Investor Relations/Events section of Arcturus’ website .
About Arcturus
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration with CSL Seqirus, U.S. BARDA for pandemic flu and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com . Please connect with us on X and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20260720082379/en/
Arcturus Therapeutics
Public Relations & Investor Relations
Neda Safarzadeh
VP, Head of IR/PR/Marketing
(858) 900-2682
IR@ArcturusRx.com
Source: Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
July 20, 2026 at 4:01 PM EDT
PDF Version
SAN DIEGO --(BUSINESS WIRE)--Jul. 20, 2026--
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will present at the following investor conference in Boston, Massachusetts :
Canaccord Genuity 46 th Annual Growth Conference (Fireside Chat)
Tuesday, August 11, 2026 ( 12:00 p.m. ET )
Webcast link can be found under Investor Relations/Events section of Arcturus’ website .
About Arcturus
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration with CSL Seqirus, U.S. BARDA for pandemic flu and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com . Please connect with us on X and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20260720082379/en/
Arcturus Therapeutics
Public Relations & Investor Relations
Neda Safarzadeh
VP, Head of IR/PR/Marketing
(858) 900-2682
IR@ArcturusRx.com
Source: Arcturus Therapeutics Holdings Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。